Cardiff drops its prostate cancer program, sending shares into a tailspin
Cardiff Oncology is joining the league of companies that have decided to scrap one of its program, leading the company’s stock to take a nose dive on Tuesday.
The company announced that it will no longer fund its clinical trials for prostate cancer and instead will focus its efforts on pancreatic and metastatic colorectal cancer.
The company is testing its lead candidate, onvansertib, a PLK1 inhibitor, along with the standard of care in a variety of indications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.